Resultados de la búsqueda 151-160 of 2810 for VEO-IBD

  1. Salud del adulto LGBTQ health - Mayo Clinic

    IBD Pride Clinic: Belonging while battling bowel disease June 28, 2024, 05:00 p.m. CDT · Mayo Clinic Minute: Fireworks safety tips June 27, 2024, 03:00 p.m. ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  3. Salud del adulto Noticias de la Mayo Clinic

    IBD Pride Clinic: Belonging while battling bowel disease June 28, 2024, 05:00 p.m. CDT · Mayo Clinic Minute: Fireworks safety tips June 27, 2024, 03:00 p.m. ...

  4. Otorrinolaringología (oído, nariz y garganta) y cirugía de cabeza y cuello - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to investigate if SD patients have vocal disorders (nodules, polyps, muscle tension dysphonia etc) more than in normal population.

  5. La salud de adolescentes y preadolescentes Noticias de la Mayo Clinic

    La salud de adolescentes y preadolescentes: desde el acondicionamiento físico y la nutrición hasta la educación sexual y el acoso.

  6. Mayo Clinic Physician Update - July 2022

    Page 1.

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  8. Salud del adulto - Mayo Clinic

    IBD Pride Clinic: Belonging while battling bowel disease June 28, 2024, 05:00 p.m. CDT · Mayo Clinic Minute: Fireworks safety tips June 27, 2024, 03:00 p.m. ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...